IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study

IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study

Introduction: Sparsentan is a novel single-molecule dual endothelin angiotensin receptor antagonist with hemodynamic and anti-inflammatory properties and is not an immunosuppressant. The ongoing phase 3 PROTECT trial examines sparsentan in adults with IgA nephropathy (IgAN). Methods: The PROTECT tri...

Full description

Bibliographic Details
Main Authors:	Jonathan Barratt, Brad Rovin, Muh Geot Wong, Charles E. Alpers, Stewart Bieler, Ping He, Jula Inrig, Radko Komers, Hiddo J.L. Heerspink, Alex Mercer, Irene L. Noronha, Jai Radhakrishnan, Michelle N. Rheault, William Rote, Howard Trachtman, Hernán Trimarchi, Vlado Perkovic
Format:	Article
Language:	English
Published:	Elsevier 2023-05-01
Series:	Kidney International Reports
Subjects:	dual endothelin angiotensin receptor antagonist ethnicity immunoglobulin A nephropathy race randomized controlled clinical trial sparsentan
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024923011956

Similar Items

Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice
by: Campbell KN, et al.
Published: (2023-12-01)

Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)
by: Radko Komers, et al.
Published: (2017-07-01)

Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis
by: Radko Komers, et al.
Published: (2020-04-01)

Endothelin Receptor Antagonists in Kidney Disease
by: Irene Martínez-Díaz, et al.
Published: (2023-02-01)

IgA nephropathy: a review of existing and emerging therapies
by: Sahibzadi Mahrukh Noor, et al.
Published: (2023-05-01)

Quantifying the integrated physiological effects of endothelin-1 on cardiovascular and renal function in healthy subjects: a mathematical modeling analysis
by: Hongtao Yu, et al.
Published: (2024-04-01)

Endothelins: Vasoactive Peptids
by: Hasan Erdoğan, et al.
Published: (2013-08-01)

Extracellular Volume Overload and Increased Vasoconstriction in Patients With Recurrent Intradialytic Hypertension
by: Peter Noel Van Buren, et al.
Published: (2016-11-01)

Pharmacological Potential of Endothelin Receptors Agonists and Antagonists
by: Jiří Patočka, et al.
Published: (2005-01-01)

Endothelin-converting enzyme-1 expression in acute and chronic liver injury in fibrogenesis
by: Tae-Jun Cho, et al.
Published: (2019-05-01)

The effect and mechanism of endothelin-1-induced intracellular free calcium in human lung adenocarcinoma cells SPC-A1
by: Juan ZHOU, et al.
Published: (2008-08-01)

Expression of Endothelin-1, Endothelin Receptor-A, and Endothelin Receptor-B in facial melasma compared to adjacent skin
by: da Silva CN, et al.
Published: (2023-10-01)

Circulating Levels of Endothelin-1 and Big Endothelin-1 in Patients with Essential Hypertension
by: Krasimir Kostov, et al.
Published: (2021-10-01)

Endothelins and Sarafotoxins: Peptides of Similar Structure and Different Function
by: Jiří Patočka, et al.
Published: (2004-01-01)

Evaluation of the Expression Levels of Endothelin-1 and its Receptor (ETAR) in Dental Lamina during Different Stages of Development of Human Fetal Teeth
by: Soussan Irani, et al.
Published: (2021-09-01)

Bosentan, a drug used in the treatment of pulmonary hypertension, can prevent development of osteoporosis
by: Duygu Köse, et al.
Published: (2021-07-01)

Endothelins as mediators in the modulation of cardiac performance
by: Smiljić Sonja, et al.
Published: (2014-01-01)

The Evidence for Sparsentan-Mediated Inhibition of <i>I</i><sub>Na</sub> and <i>I</i><sub>K(erg)</sub>: Possibly Unlinked to Its Antagonism of Angiotensin II or Endothelin Type a Receptor
by: Tzu-Hsien Chuang, et al.
Published: (2021-12-01)

Blockade of Endothelin-1 Receptor Type B Ameliorates Glucose Intolerance and Insulin Resistance in a Mouse Model of Obstructive Sleep Apnea
by: Jan Polak, et al.
Published: (2018-05-01)

Endocan, ET-1, and ETAR Expression Profiles in Unicystic Ameloblastoma, Multicystic Ameloblastoma, and Ameloblastic Carcinoma
by: Soussan Irani, et al.
Published: (2019-07-01)

Current status of bosentan for treatment of pulmonary hypertension
by: Raja Shahzad, et al.
Published: (2008-01-01)

Endothelin signalling mediates experience-dependent myelination in the CNS
by: Matthew Swire, et al.
Published: (2019-10-01)

THE ROLE OF ENDOTHELIN-1 IN VASCULAR HEMOSTASIS OF PERIODONTAL TISSUES
by: N.V. Yarychkivska
Published: (2017-03-01)

Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta‐Analysis of 4894 Patients From 24 Randomized Double‐Blind Placebo‐Controlled Clinical Trials
by: Anhua Wei, et al.
Published: (2016-10-01)

Effect of cold stress on ovarian & uterine microcirculation in rats and the role of endothelin system
by: Di Wang, et al.
Published: (2020-04-01)

Disruption of the endothelin A receptor in the nephron causes mild fluid volume expansion
by: Stuart Deborah, et al.
Published: (2012-12-01)

Is endothelin gene polymorphism associated with postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting?
by: Ira Dhawan, et al.
Published: (2017-01-01)

Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease
by: J. David Smeijer, et al.
Published: (2023-09-01)

Endothelin-based markers for endothelial dysfunction in chemotherapy-induced cardiotoxicity
by: Gabrielle Boutin, et al.
Published: (2023-12-01)

Novel Dual Endothelin Inhibitors in the Management of Resistant Hypertension
by: Chrysoula Boutari, et al.
Published: (2023-03-01)

PLASMA CONCENTRATION OF ENDOTHELIN-1 IN PATIENTS WITH HYPERTENSION ASSOCIATED WITH OBESITY, DEPENDING ON THE LYS198ASN POLYMORPHISM OF THE ENDOTHELIN-1 GENE
by: Yu. O. Smiianova
Published: (2021-03-01)

Gender differences in vascular expression of endothelin and ET A/ET B receptors, but not in calcium handling mechanisms, in deoxycorticosterone acetate-salt hypertension
by: F.L. David, et al.
Published: (2002-09-01)

Pipersentan: A De Novo Synthetic Endothelin Receptor Antagonist that Inhibits Monocrotaline- and Hypoxia-Induced Pulmonary Hypertension
by: Zeyu Zhang, et al.
Published: (2022-06-01)

Endothelin signalling in iridophore development and stripe pattern formation of zebrafish
by: Jana Krauss, et al.
Published: (2014-05-01)

Determination of the Granulosa Cell-Specific Endothelin Receptor A Deletion on Ovarian Function
by: Jong-Ki Cho
Published: (2014-06-01)

Physiologically‐based pharmacokinetic model of sparsentan to evaluate drug–drug interaction potential
by: Nikunjkumar K. Patel, et al.
Published: (2024-02-01)

Population pharmacokinetic analysis of sparsentan in healthy volunteers and patients with focal segmental glomerulosclerosis
by: Russell Wada, et al.
Published: (2023-08-01)

Acute nitric oxide synthase inhibition and endothelin-1-dependent arterial pressure elevation
by: Robert eRapoport
Published: (2014-04-01)

The Endothelin Receptor Antagonist Macitentan Inhibits Human Cytomegalovirus Infection
by: Natalia Landázuri, et al.
Published: (2021-11-01)

Cryo-EM structure of the endothelin-1-ETB-Gi complex
by: Fumiya K Sano, et al.
Published: (2023-04-01)